Advanced imaging of primary prostate cancer
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Prostate cancer is the most commonly diagnosed cancer among men in Sweden and remains a significant cause of death. Advances in imaging have enabled more precise disease characterization and decision-making in clinical management. This thesis explores primarily the role of advanced molecular imaging modalities—Positron emission tomography (PET) combined with Computed tomography (CT) or Magnetic resonance imaging (MRI), and Single- photon emission computed tomography (SPECT) —in primary staging and disease evaluation of prostate cancer. In Studies I and II, the diagnostic performance and robustness of Prostate-specific membrane antigen (PSMA) PET/CT imaging was assessed by comparing ordered subset expectation maximization (OSEM) and block sequential regularized expectation maximization (BSREM) algorithms, in study I, and varying image acquisition times, in study II. The compared reconstruction methods produced comparable lesion detectability. Also, image acquisition times could be varied from three down to one minute per bed position, without compromising clinical interpretation. Study III assessed PSMA SPECT/CT —an often more accessible and cost-effective modality — versus MRI and systematic biopsies. Findings indicate that PSMA SPECT/CT offers promising accuracy in localizing intraprostatic disease. In some settings it might be a complement, or substitute, to MRI. Study IV investigated PSMA expression dynamics during short-term non- steroidal antiandrogen (NSAA) therapy using dynamic PET/MRI. While hormonal therapy influences tracer uptake heterogeneously, quantitative analysis suggested upregulation of PSMA expression in hormone-sensitive disease. This gives insight into the variable imaging response post NSAA therapy seen previously and can have implications for future theranostic approaches. In Study V, safety and biodistribution of a novel PET radiotracer, [68Ga]Ga- NOTA-PEG2-RM26, targeting the gastrin-releasing peptide receptor (GRPR), was assessed in a first-in-human trial. The tracer was well tolerated and demonstrated favorable biodistribution, supporting further development of GRPR-targeted imaging as a complementary or alternative tool in prostate cancer detection. Collectively, these studies contribute to the optimization of prostate cancer imaging. This thesis advances understanding of tracer kinetics, technical factors, and biologically induced uptake variations, thereby supporting the integration of targeted imaging in the staging and management of prostate cancer. As radioligand therapy emerges, findings from this thesis may be of value for diagnostic strategies and for therapeutic planning. List of scientific papers I. Comparison of Regularized Reconstruction and Ordered Subset Expectation Maximization Reconstruction in the Diagnostics of Prostate Cancer Using Digital Time-of-Flight [68Ga]Ga-PSMA-11 PET/CT Imaging. Olof Jonmarker, Rimma Axelsson, Ted Nilsson, Stefan Gabrielson. Diagnostics (Basel), 2021 Mar 31;11(4):630. https://doi.org/10.3390/diagnostics11040630 II. [18F]F-PSMA-1007 PET imaging optimization and inter-rater reliability - a comparison of three different reconstructions read by four radiologists. Olof Jonmarker, Ted Nilsson, Rimma Axelsson, Lovisa Hult Ericson, Thuy A Tran, Antonios Tzortzakakis, Irina Savitcheva, Maria Holstensson. Nuclear Medicine Communications, 2024 May 1;45(5):389-395. https://doi.org/10.1097/mnm.0000000000001823 III. Retrospective analysis of [99mTc]Tc-HYNIC-PSMA SPECT CT in patients with prostate cancer. Olof Jonmarker, Michael Sunderland, Lotte Steffens, Carl Samuelsson, Janvi Puri, Darin O'Keeffe, Stefan Gabrielson. Nuclear Medicine Communications, 2026 Jan 1;47(1):41-4. https://doi.org/10.1097/mnm.0000000000002060 IV. The impact of short-term androgen deprivation therapy on lesion baseline [68Ga]Ga-PSMA-11 binding potential and MR apparent diffusion restriction coefficient in hormone-sensitive, prostate cancer patients; a longitudinal prospective study. Alejandro Sanchez-Crespo, Olof Jonmarker, Fredrik Jäderling, Stefan Karlsson, Mats Olsson, Chunde Li, Rimma Axelsson. EJNMMI Res. 2025 Oct 2;15(1):127. https://doi.org/10.1186/s13550-025-01328-1 V. First-in-human experience with GRPR antagonist [68Ga]Ga- NOTA-PEG2-RM26 in prostate and breast cancer patients using PET/CT. Annie Bjäreback, Olof Jonmarker, Antonios Tzortzakakis, Emma Jussing, Chunde Li, Renske Altena, Cecilia Hindorf, Anna Orlova, Rimma Axelsson, Thuy A Tran. EJNMMI Res. 2025 Feb 20;15(1):12. https://doi.org/10.1186/s13550-025-01204-y
Fields of Study & Subjects
Medical Imaging Techniques and Applications
Prostate Cancer Diagnosis and Treatment
Radiopharmaceutical Chemistry and Applications
Publication details
- Publication date
- 27 March 2026
- Language
- EN